World Library  
Flag as Inappropriate
Email this Article

Slamf1

Article Id: WHEBN0014761508
Reproduction Date:

Title: Slamf1  
Author: World Heritage Encyclopedia
Language: English
Subject: CD1A, CD109, CD153, IGSF2, NKG2
Collection: Clusters of Differentiation
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Slamf1

Signaling lymphocytic activation molecule family member 1

Rendering of SLAMF1 from PDB
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; CD150; CDw150; SLAM
External IDs GeneCards:
RNA expression pattern
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

Signaling lymphocytic activation molecule is a protein that in humans is encoded by the SLAMF1 gene.[1][2]

SLAMF1 has also recently has been designated CD150 (cluster of differentiation 150).


Interactions

SLAMF1 has been shown to interact with PTPN11,[3][4] SH2D1A[3][5] and SH2D1B.[4]

References

  1. ^ Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G (August 1995). "A novel receptor involved in T-cell activation". Nature 376 (6537): 260–3.  
  2. ^ "Entrez Gene: SLAMF1 signaling lymphocytic activation molecule family member 1". 
  3. ^ a b Howie, Duncan; Simarro María; Sayos Joan; Guirado Maria; Sancho Jaime; Terhorst Cox (February 2002). "Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation". Blood (United States) 99 (3): 957–65.  
  4. ^ a b Morra, M; Lu J, Poy F, Martin M, Sayos J, Calpe S, Gullo C, Howie D, Rietdijk S, Thompson A, Coyle A J, Denny C, Yaffe M B, Engel P, Eck M J, Terhorst C (November 2001). "Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells". EMBO J. (England) 20 (21): 5840–52.  
  5. ^ Morra, M; Simarro-Grande M, Martin M, Chen A S, Lanyi A, Silander O, Calpe S, Davis J, Pawson T, Eck M J, Sumegi J, Engel P, Li S C, Terhorst C (September 2001). "Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients". J. Biol. Chem. (United States) 276 (39): 36809–16.  

Further reading

  • Punnonen J, Cocks BG, Carballido JM, et al. (1997). "Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes.". J. Exp. Med. 185 (6): 993–1004.  
  • Sayos J, Wu C, Morra M, et al. (1998). "The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.". Nature 395 (6701): 462–9.  
  • Mikhalap SV, Shlapatska LM, Berdova AG, et al. (1999). "CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis.". J. Immunol. 162 (10): 5719–27.  
  • Li SC, Gish G, Yang D, et al. (2000). "Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A.". Curr. Biol. 9 (23): 1355–62.  
  • Rogge L, Bianchi E, Biffi M, et al. (2000). "Transcript imaging of the development of human T helper cells using oligonucleotide arrays.". Nat. Genet. 25 (1): 96–101.  
  • Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000). "SLAM (CDw150) is a cellular receptor for measles virus.". Nature 406 (6798): 893–7.  
  • Lewis J, Eiben LJ, Nelson DL, et al. (2001). "Distinct interactions of the X-linked lymphoproliferative syndrome gene product SAP with cytoplasmic domains of members of the CD2 receptor family.". Clin. Immunol. 100 (1): 15–23.  
  • Morra M, Simarro-Grande M, Martin M, et al. (2001). "Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients.". J. Biol. Chem. 276 (39): 36809–16.  
  • Kruse M, Meinl E, Henning G, et al. (2001). "Signaling lymphocytic activation molecule is expressed on mature CD83+ dendritic cells and is up-regulated by IL-1 beta.". J. Immunol. 167 (4): 1989–95.  
  • Bleharski JR, Niazi KR, Sieling PA, et al. (2001). "Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines.". J. Immunol. 167 (6): 3174–81.  
  • Morra M, Lu J, Poy F, et al. (2001). "Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells.". EMBO J. 20 (21): 5840–52.  
  • Howie D, Simarro M, Sayos J, et al. (2002). "Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): CD150/SAP binding and CD150-mediated costimulation.". Blood 99 (3): 957–65.  
  • Murabayashi N, Kurita-Taniguchi M, Ayata M, et al. (2002). "Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification.". Microbes Infect. 4 (8): 785–94.  
  • Li C, Iosef C, Jia CY, et al. (2003). "Dual functional roles for the X-linked lymphoproliferative syndrome gene product SAP/SH2D1A in signaling through the signaling lymphocyte activation molecule (SLAM) family of immune receptors.". J. Biol. Chem. 278 (6): 3852–9.  
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903.  
  • Hahm B, Arbour N, Naniche D, et al. (2003). "Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule.". J. Virol. 77 (6): 3505–15.  
  • Del Valle JM, Engel P, Martín M (2003). "The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2).". J. Biol. Chem. 278 (19): 17430–7.  
  • Ferrand V, Li C, Romeo G, Yin L (2003). "Absence of SLAM mutations in EBV-associated lymphoproliferative disease patients.". J. Med. Virol. 70 (1): 131–6.  
  • Laaksonen K, Junikka M, Lahesmaa R, et al. (2004). "In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy.". J. Allergy Clin. Immunol. 112 (6): 1171–7.  


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.